DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
50 hedge funds and large institutions have $5.35M invested in DMK Pharmaceuticals Corporation Common Stock in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 10 closing their positions.
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
2% less funds holding
Funds holding: 51 → 50 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
45% less capital invested
Capital invested by funds: $9.69M → $5.35M (-$4.34M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $24K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.48M |
| 2 |
6CM
683 Capital Management
New York
|
+$1.12M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$907K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$188K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$141K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$1.81M |
| 2 |
Morgan Stanley
New York
|
-$564K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$115K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$70.5K |
| 5 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$38K |
DMK Hedge Fund Activity: Q3 2019 in Review
50 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q3 2019, worth a combined $5.35M — down 45% from $9.69M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of DMK and 9 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 10 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.48M. The largest seller was First Manhattan, exiting entirely with an estimated $1.81M sold.
- 50 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q3 2019, down from 51 in Q2 2019.
- Funds reported $5.35M of DMK Pharmaceuticals Corporation Common Stock stock for Q3 2019, down 45% quarter-over-quarter.
- 9 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q3 2019 and 10 closed out, a net change of -1 holder.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q3 2019 was Anson Funds Management, an estimated $1.48M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q3 2019 was First Manhattan, an estimated $1.81M sold.
Based on aggregated 13F filings for Q3 2019.